PS

Pragati Singh

Active Director Director DIN 08616955
DIN 08616955 First appointment Nov 2019 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2019
Shareholding value •••• Premium profile

About Pragati Singh

Data last updated:

Pragati Singh is a Director at Ry Pharma Private Limited (since 2019). The company operates in Chemicals. Ry Pharma Private Limited reported revenue of ₹5.9 Lakh (FY 2024).

DIN 08616955
Primary Designation Director
Industry Chemicals
First Appointment 21 Nov 2019
Oldest Company Age 7 yrs
Largest company Ry Pharma Private Limited · ₹5.9 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Ry Pharma Private Limited U24100UP2019PTC119919
Director21 Nov 20192019₹5.9 Lakh (FY 2024)Active

Board colleagues of Pragati Singh

NameDINCompanyDesignation
Vijay Shankar Pal08531140Ry Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Ry Pharma Private Limited
Premium access

Shareholding and investment profile for Pragati Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Pragati Singh

Pragati Singh currently holds 1 directorship: Ry Pharma Private Limited (Director, since 21 Nov 2019, revenue ₹5.9 Lakh (FY 2024)).

Pragati Singh was first appointed on 21 Nov 2019 as Director at Ry Pharma Private Limited.

The current boards of Pragati Singh's companies include Vijay Shankar Pal (Ry Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available